Brain47Brain47Join Brain47
2B70

iShares NASDAQ US Biotechnology UCITS ETF

ETFs & Funds · EUR · F

2B70ETF

Price

€7.448

+1.76%

Cap

—

Earnings

—

30d Trend

-1.6%

2B70
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityModerate

22% annualised over 90 days

BRAIN47 SIGNAL

0
STRONG
Risk Level25
Momentum55
Technical52
Fund Quality75
Cost Efficiency67

Raw weighted: 67×Macro 0.99 (−1%)=66

RISK

25/100
90d Volatility
22.1%Moderate
ATR %
1.8%Normal
Max Drawdown (1Y)
-7.9%Resilient

MOMENTUM

55/100
1M Return
+1.9%Stable

TECHNICAL

52/100
RSI (14)
54.8Neutral
MACD
+0.01Bullish momentum
Bollinger Band
75%Mid-range
Trend Quality (KER)
0.035Noisy/choppy

FUND QUALITY

75/100
Replication
PhysicalHolds actual assets
Holdings
269 positionsWell diversified
Domicile
Ireland (tax-efficient)15% US withholding tax

COST EFFICIENCY

67/100
Expense Ratio
0.35%Moderate
Fund Size (AUM)
$1.3BMid-size

Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months45
3-12 months49
1-5+ years ★72

Long-term compounder — quality business with growth runway

BRAIN47'S ASSESSMENT

I rate iShares NASDAQ US Biotechnology UCITS ETF at 66/100 — a STRONG reading on the Brain47 Signal. The strongest factor is risk management at 75/100. I classify this as a defensive position with the strongest thesis on a long-term horizon.

PAST PERFORMANCE

1 MONTH

+1.9%

3 MONTHS

-1.0%

12 MONTHS

—

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

Long-term compounder — quality business with growth runway. low-risk profile and Fund Quality (75) are the primary strengths. Historical volatility is normal at 22%. I classify this as a defensive holding — stability characteristics and high business quality provide portfolio ballast.

defensiveScore: 66/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.